Company Active LTD

Company profile

Mologic LTD.

AgriAlert | Global Leader In Animal Health Diagnostics | GADx

At GADx we have a strong history of developing personalized lateral flow rapid diagnostic tests for livestock, aquaculture, crops...

CRN
04784437
Founded
2003
Age
23

Overview

Legal name
MOLOGIC LTD.
Region
South East England
Registered address
BUILDING 109 BEDFORD TECHNOLOGY PARK
THURLEIGH
BEDFORD
BEDFORDSHIRE
ENGLAND
MK44 2YA
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller Controls 1
1
Company Active LTD
Mologic LTD.
CRN 04784437
2
Direct and ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC-LIMITED-EXEMPTION
Global Access Health
CRN 13372740

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

14 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

28 Mar
2026

Accounts With Accounts Type Small

Accounts Analysed

AA | Transaction MzUxMzExMzI1MGFkaXF6a2N4

Published 28 Mar 2026 09:37

30 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

02 Jun
2003

Incorporated

Inception

Company registered at Companies House

Public funding

18 awards
First funded
2007
Funded years
2007, 2008, 2009, 2010, 2011, 2012, 2016, 2017, 2018, 2021, 2022, 2025, 2026
Age at first award
4 years

Projects

2026 Collaborative R&D

HERALD: Revolutionizing Livestock Disease Detection Through Advanced Diagnostics

1 Apr 2026 to 31 Mar 2027

Awarded
£50,838
Total cost £84,730

**HERALD (Health Enhancement through Rapid Assessment of Livestock Diseases)** is a collaborative project delivering fast, practical diagnostics for Johne's disease (JD) in cattle, with limited feasibility work preparing the platform for future bovine tuberculosis applications. JD is widespread and costly for dairy and beef producers, undermining animal w...

2025 EU-Funded Lead participant

Diagnostic and Antibiotic Stewardship for Urinary Tract Infections Using Fit-for-Purpose Diagnostic Tools

1 Mar 2025 to 31 Aug 2028

Awarded
£538,611
Total cost £538,611

Urinary Tract Infections (UTIs) and antimicrobial resistance (AMR) pose significant global health threats, characterised by high incidence and mortality. However, in Sub-Saharan Africa (SSA), there is often a lack of accessible diagnostics to guide proper treatment and therapy monitoring. Our objectives are as follows: (1) Develop and validate a two-tier ...

2022 EU-Funded Lead participant

Digital Innovations and for Infectious Diseases in Africa

1 Oct 2022 to 30 Sep 2027

Awarded
£346,769
Total cost £346,769

no public description

2022 EU-Funded Lead participant

A holistic approach in patient management and epidemic surveillance through convergence of diagnostic technologies, capacity building and stakeholder engagement

1 Sep 2022 to 31 Aug 2025

Awarded
£767,222
Total cost £767,222

no public description

2021 Study

Establishment of mammalian cell expression systems for the production of essential low cost protein reagents for development of rapid diagnostics

1 Jan 2021 to 31 Dec 2023

Awarded
£0
Total cost £0

The current SARS-CoV-2 pandemic has highlighted the need for access to rapidly produced, reliable diagnostics with the required sensitivity and specificity at a cost that makes these widely accessible to lower and middle income (LMICs) as well as higher income countries. Protein based diagnostic development and manufacture is reliant upon the availability...

2018 Small Business Research Initiative Lead participant

IMPROVED Q FEVER VACCINE (DSTL, PHE, ICENI DX & MOLOGIC)

1 Feb 2018 to 31 Mar 2022

Awarded
£1,993,857
Total cost £1,993,857

This project addresses the need for new vaccines for global epidemics by the development of a virus-like particle (VLP) based platform technology to deliver a vaccine against Q Fever. The causal agent of Q fever, Coxiella burnetii has been identified as an agent of concern due to its low infectious dose, the ability of the organism to survive for long per...

2017 Small Business Research Initiative Lead participant

COPD Exacerbation Alert for patient stratification

1 Jul 2017 to 31 Mar 2021

Awarded
£2,000,000
Total cost £2,000,000

COPD is the second most common cause of emergency admissions in the UK, responsible for one in eight (130,000) acute adult medical admissions. It is a global problem, with 210 million sufferers and 3 million deaths annually (WHO, 2009). There are 1.2M COPD patients in the UK. Patients with COPD have daily symptoms, a poorer health status, reduced exercise...

2017 Collaborative R&D Lead participant

Semi-automated on-site quantification of airborne pathogen inoculum to predict the strawberry fruit rot risks

1 Apr 2017 to 30 Jun 2020

Awarded
£291,071
Total cost £415,815

Reducing fungal fruit rot is a priority in strawberry production in the UK; annual economic losses due to fungal rotting are usually between £30 to £60M. Rot is mainly caused by Botrytis cinerea, Mucor spp. and Rhizopus spp., with their relative prevalence varying over time and growing site. Most strawberry production in the UK is under protection where t...

2017 Collaborative R&D Lead participant

SEPSIS Alert Test

1 Jan 2017 to 30 Jun 2019

Awarded
£878,634
Total cost £1,255,191

Sepsis is one of the most common deadly diseases and one of the leading causes of death in the developed world exerting a huge human and economic toll. In the UK there are over 100,000 cases and 37,000 deaths annually. Rapid diagnosis is critical to the effective treatment of the patient and offers the prospect of reduced mortality but existing diagnostic...

2016 Small Business Research Initiative Lead participant

Improved Q Fever Vaccine (DSTL, PHE, ICENI DX & Mologic)

1 Sep 2016 to 31 Aug 2017

Awarded
£522,800
Total cost £522,800

Virus-like particles (VLPs) are a flexible delivery platform that provides potential for presenting multiple antigens to the immune system concurrently. Hepatitis B core antigen self assembles to form highly stable, immunogenic VLPs in a relatively low cost yeast expression system. The viral protein can be adapted to display foreign antigens on spikes tha...

2016 Small Business Research Initiative Lead participant

COPD Exacerbation Alert for patient stratification

1 Mar 2016 to 30 Nov 2016

Awarded
£150,000
Total cost £150,000

Our target is to develop a simple, easy to use, diagnostic system for use in the home by COPD patients to gain early warning of acute exacerbation (AECOPD) and stratify them to the most suitable and effective therapy. This will determine the use of antibiotic, anti-inflammatory or bronchodilator medication (combinations of some of these might be required)...

2012 Collaborative R&D Lead participant

Project SABRINA (Sepsis Alert Biomarkers Resolved In a Novel Assay)

1 Jul 2012 to 30 Jun 2015

Awarded
£241,492
Total cost £590,157

A simple, easy to use, rapid, inexpensive, effective, point of care (POC) immunodiagnostic system for early confirmation of sepsis in at-risk patients is to be developed and validated. The biomarkers will include IL-6, C-reactive protein and soluble ICAM-1. These known biomarkers will be integrated via a new algorithm with other physical/clinical indicato...

Product types

Collaborative R&D EU-Funded Feasibility Studies Small Business Research Initiative Study